Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Relapsed or Refractory Multiple Myeloma
Related studies linked through entity extraction aliases.
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3